Abstract Number: 0589 • ACR Convergence 2024
Time to Clinical Response to Secukinumab Across Disease Domains Among Patients with Psoriatic Arthritis: A Pooled Post Hoc Analysis of 4 Phase 3 Trials
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease that can manifest with considerable clinical heterogeneity. Secukinumab demonstrated improvements across the updated Group for Research and…Abstract Number: 0825 • ACR Convergence 2024
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator (BRAVO): 6-month Outcomes of a Longitudinal Cohort Study
Background/Purpose: To evaluate the effectiveness and safety of rituximab (RTX) biosimilars compared to the originator in Canadians with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis…Abstract Number: 1106 • ACR Convergence 2024
Factors Associated with Relapse in Giant Cell Arteritis Treated with Tocilizumab. Multicenter Open-label Study of 407 Patients
Background/Purpose: Tocilizumab (TCZ) is the only biological drug approved for the treatment of giant cell arteritis (GCA). Clinical trials were performed with intravenous (IV) and…Abstract Number: 1454 • ACR Convergence 2024
Treatment Patterns, Clinical Characteristics, and Patient-Reported Outcomes Among Patients with Axial Spondyloarthritis Treated in Real-World Rheumatology Practices in the US
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic immune-mediated rheumatic disease with high comorbidity burden. Biologic disease-modifying anti-rheumatic drugs (bDMARDs) and patient-reported outcomes (PROs) are increasingly…Abstract Number: 1544 • ACR Convergence 2024
Comparison of Efficacy and Safety Between Belimumab and Telitacicept in the Treatment of Systemic Lupus Erythematosus
Background/Purpose: B cells play an important role in the pathogenesis of systemic lupus erythematosus(SLE).Multiple biological agents with B lymphocyte as the therapeutic target have recently emerged…Abstract Number: 1988 • ACR Convergence 2024
A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
Background/Purpose: Nipocalimab is a human IgG1 monoclonal antibody targeting the neonatal Fc receptor (FcRn) that selectively reduces IgG levels without impacting antigen presentation, T- and…Abstract Number: 2257 • ACR Convergence 2024
Comparison of the Safety and Effectiveness of Originator Rituximab (Mabthera®) versus Biosimilar (Riximyo®) in Rheumatoid Arthritis: A Retrospective Unicentric Analysis
Background/Purpose: Immunobiological drugs emerged as a revolutionary option for treating inflammatory chronic rheumatic diseases, particularly rheumatoid arthritis (RA). However, the extremely high costs associated with…Abstract Number: 2440 • ACR Convergence 2024
Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient’s Characteristics
Background/Purpose: Anifrolumab is a biological treatment with recent approval for systemic lupus erythematosus (SLE), supported by its efficacy in clinical trials. However, data from real…Abstract Number: 0001 • ACR Convergence 2024
Type I Interferon and Anifrolumab Effects on Bone Marrow and Blood Plasma Cells in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of pathogenic anti-nuclear antibodies (ANA) by plasma cells (PC). Importantly, long-lived plasma…Abstract Number: 0390 • ACR Convergence 2024
Treatment Effectiveness Following Switching from Initial TNF Inhibitor in Juvenile Idiopathic Arthritis
Background/Purpose: Although the increasing availability of biologic therapies has significantly improved outcomes for patients with JIA, a substantial proportion of patients require switching from the…Abstract Number: 0512 • ACR Convergence 2024
Co-stimulatory Blockade Causes Targeted Quantitative and Clonotypic Contractions in Extrafollicular B-cell Subsets in Seropositive RA Patients
Background/Purpose: Of all approved biologic therapies, other than anti-CD20 depletion only CTLA4-Ig/abatacept treatment reduces levels of pathologic autoantibodies. Herein, our primary goal has been to…Abstract Number: 0590 • ACR Convergence 2024
Efficacy of Secukinumab Across the Axial Spondyloarthritis Spectrum Among Patients Grouped by Age (≥40 Years vs < 40): A PostHoc Analysis of 6 Phase 3 Trials
Background/Purpose: Secukinumab is an IL-17 inhibitor approved to treat axial spondyloarthritis (axSpA), including radiographic (r)-axSpA and non-radiographic (nr)-axSpA. Recent ASAS-EULAR recommendations highlight the importance of…Abstract Number: 0827 • ACR Convergence 2024
Oral Corticosteroid-Sparing Effects of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Results up to 7.4 Years from the Long-Term Access Programme
Background/Purpose: EGPA is a severe, rare, relapsing/remitting inflammatory disease, in which chronic or high oral corticosteroid (OCS) doses lead to adverse effects, adding to disease…Abstract Number: 1120 • ACR Convergence 2024
Long-Term Echocardiographic Findings in Idiopathic Recurrent Pericarditis Patients Treated with Anakinra
Background/Purpose: Idiopathic recurrent pericarditis (IRP) is characterized by recurrent pericarditis attacks, and autoinflammatory pattern has been highlighted due to similarities in both clinical features and…Abstract Number: 1455 • ACR Convergence 2024
Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients with Psoriatic Arthritis
Background/Purpose: Secondary failure to biologic therapy is challenging and contributes to the complexity of managing psoriatic arthritis (PsA). In this study, we aimed to define…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 54
- Next Page »